A Nuclear Magnetic Resonance Spectroscopy Method in Characterization of Blood Metabolomics for Alzheimer’s Disease
There is currently a crucial need for improved diagnostic techniques and targeted treatment methods for Alzheimer’s disease (AD), a disease which impacts millions of elderly individuals each year. Metabolomic analysis has been proposed as a potential methodology to better investigate and understand...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Metabolites |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-1989/12/2/181 |
| _version_ | 1827653942098526208 |
|---|---|
| author | JianXiang Weng Isabella H. Muti Anya B. Zhong Pia Kivisäkk Bradley T. Hyman Steven E. Arnold Leo L. Cheng |
| author_facet | JianXiang Weng Isabella H. Muti Anya B. Zhong Pia Kivisäkk Bradley T. Hyman Steven E. Arnold Leo L. Cheng |
| author_sort | JianXiang Weng |
| collection | DOAJ |
| description | There is currently a crucial need for improved diagnostic techniques and targeted treatment methods for Alzheimer’s disease (AD), a disease which impacts millions of elderly individuals each year. Metabolomic analysis has been proposed as a potential methodology to better investigate and understand the progression of this disease. In this report, we present our AD metabolomics results measured with high resolution magic angle spinning (HRMAS) nuclear magnetic resonance (NMR) on human blood plasma samples obtained from AD and non-AD subjects. Our study centers on developments of AD and non-AD metabolomics differentiating models with procedures of quality assurance (QA) and quality control (QC) through pooled samples. Our findings suggest that analysis of blood plasma samples using HRMAS NMR has the potential to differentiate between diseased and healthy subjects, which has important clinical implications for future improvements in AD diagnosis methodologies. |
| first_indexed | 2024-03-09T21:27:42Z |
| format | Article |
| id | doaj.art-8caa134326ac46bab2b78ae109404835 |
| institution | Directory Open Access Journal |
| issn | 2218-1989 |
| language | English |
| last_indexed | 2024-03-09T21:27:42Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Metabolites |
| spelling | doaj.art-8caa134326ac46bab2b78ae1094048352023-11-23T21:05:42ZengMDPI AGMetabolites2218-19892022-02-0112218110.3390/metabo12020181A Nuclear Magnetic Resonance Spectroscopy Method in Characterization of Blood Metabolomics for Alzheimer’s DiseaseJianXiang Weng0Isabella H. Muti1Anya B. Zhong2Pia Kivisäkk3Bradley T. Hyman4Steven E. Arnold5Leo L. Cheng6Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USADepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USADepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USADepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USADepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USADepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USADepartments of Radiology and Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USAThere is currently a crucial need for improved diagnostic techniques and targeted treatment methods for Alzheimer’s disease (AD), a disease which impacts millions of elderly individuals each year. Metabolomic analysis has been proposed as a potential methodology to better investigate and understand the progression of this disease. In this report, we present our AD metabolomics results measured with high resolution magic angle spinning (HRMAS) nuclear magnetic resonance (NMR) on human blood plasma samples obtained from AD and non-AD subjects. Our study centers on developments of AD and non-AD metabolomics differentiating models with procedures of quality assurance (QA) and quality control (QC) through pooled samples. Our findings suggest that analysis of blood plasma samples using HRMAS NMR has the potential to differentiate between diseased and healthy subjects, which has important clinical implications for future improvements in AD diagnosis methodologies.https://www.mdpi.com/2218-1989/12/2/181Alzheimer’s diseasemetabolomicsnuclear magnetic resonance spectroscopyblood plasma |
| spellingShingle | JianXiang Weng Isabella H. Muti Anya B. Zhong Pia Kivisäkk Bradley T. Hyman Steven E. Arnold Leo L. Cheng A Nuclear Magnetic Resonance Spectroscopy Method in Characterization of Blood Metabolomics for Alzheimer’s Disease Metabolites Alzheimer’s disease metabolomics nuclear magnetic resonance spectroscopy blood plasma |
| title | A Nuclear Magnetic Resonance Spectroscopy Method in Characterization of Blood Metabolomics for Alzheimer’s Disease |
| title_full | A Nuclear Magnetic Resonance Spectroscopy Method in Characterization of Blood Metabolomics for Alzheimer’s Disease |
| title_fullStr | A Nuclear Magnetic Resonance Spectroscopy Method in Characterization of Blood Metabolomics for Alzheimer’s Disease |
| title_full_unstemmed | A Nuclear Magnetic Resonance Spectroscopy Method in Characterization of Blood Metabolomics for Alzheimer’s Disease |
| title_short | A Nuclear Magnetic Resonance Spectroscopy Method in Characterization of Blood Metabolomics for Alzheimer’s Disease |
| title_sort | nuclear magnetic resonance spectroscopy method in characterization of blood metabolomics for alzheimer s disease |
| topic | Alzheimer’s disease metabolomics nuclear magnetic resonance spectroscopy blood plasma |
| url | https://www.mdpi.com/2218-1989/12/2/181 |
| work_keys_str_mv | AT jianxiangweng anuclearmagneticresonancespectroscopymethodincharacterizationofbloodmetabolomicsforalzheimersdisease AT isabellahmuti anuclearmagneticresonancespectroscopymethodincharacterizationofbloodmetabolomicsforalzheimersdisease AT anyabzhong anuclearmagneticresonancespectroscopymethodincharacterizationofbloodmetabolomicsforalzheimersdisease AT piakivisakk anuclearmagneticresonancespectroscopymethodincharacterizationofbloodmetabolomicsforalzheimersdisease AT bradleythyman anuclearmagneticresonancespectroscopymethodincharacterizationofbloodmetabolomicsforalzheimersdisease AT stevenearnold anuclearmagneticresonancespectroscopymethodincharacterizationofbloodmetabolomicsforalzheimersdisease AT leolcheng anuclearmagneticresonancespectroscopymethodincharacterizationofbloodmetabolomicsforalzheimersdisease AT jianxiangweng nuclearmagneticresonancespectroscopymethodincharacterizationofbloodmetabolomicsforalzheimersdisease AT isabellahmuti nuclearmagneticresonancespectroscopymethodincharacterizationofbloodmetabolomicsforalzheimersdisease AT anyabzhong nuclearmagneticresonancespectroscopymethodincharacterizationofbloodmetabolomicsforalzheimersdisease AT piakivisakk nuclearmagneticresonancespectroscopymethodincharacterizationofbloodmetabolomicsforalzheimersdisease AT bradleythyman nuclearmagneticresonancespectroscopymethodincharacterizationofbloodmetabolomicsforalzheimersdisease AT stevenearnold nuclearmagneticresonancespectroscopymethodincharacterizationofbloodmetabolomicsforalzheimersdisease AT leolcheng nuclearmagneticresonancespectroscopymethodincharacterizationofbloodmetabolomicsforalzheimersdisease |